Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 2,000 Shares of Stock

Key Points

• Jazz Pharmaceuticals Director Bruce Cozadd sold 2,000 shares at an average price of $131.78, reducing his ownership by 0.48%.
• The company reported a quarterly EPS of ($8.25), missing estimates and reflecting a negative net margin of 9.91% despite a 2.1% year-over-year revenue increase.
• Equities analysts have a consensus rating of "Moderate Buy" for Jazz Pharmaceuticals, with price targets ranging from $152 to $205.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) Director Bruce Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $131.78, for a total value of $263,560.00. Following the sale, the director owned 412,326 shares of the company's stock, valued at approximately $54,336,320.28. This trade represents a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jazz Pharmaceuticals Stock Up 1.7%

Shares of Jazz Pharmaceuticals stock traded up $2.27 during trading on Friday, hitting $139.48. 1,051,391 shares of the stock traded hands, compared to its average volume of 722,485. The firm has a market cap of $8.46 billion, a P/E ratio of -20.73, a price-to-earnings-growth ratio of 8.51 and a beta of 0.28. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The stock's fifty day simple moving average is $123.75 and its 200 day simple moving average is $115.84.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Truist Financial raised their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Morgan Stanley raised their price target on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an "overweight" rating in a research note on Wednesday, September 24th. Deutsche Bank Aktiengesellschaft assumed coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock. The Goldman Sachs Group raised their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research note on Friday, August 29th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Jazz Pharmaceuticals in a research note on Saturday, September 27th. Fourteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $178.93.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LSV Asset Management boosted its holdings in Jazz Pharmaceuticals by 3.6% in the second quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company's stock worth $271,003,000 after acquiring an additional 87,576 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Jazz Pharmaceuticals by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after acquiring an additional 293,360 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Jazz Pharmaceuticals by 11.4% in the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company's stock worth $198,159,000 after acquiring an additional 191,637 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Jazz Pharmaceuticals by 3.6% in the second quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company's stock worth $182,664,000 after acquiring an additional 59,252 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after acquiring an additional 391,660 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.